Cancer-cell-killing peptide (PNC-27)
A lab-made peptide that punches holes in cancer cells while leaving normal cells unharmed; experimental, not yet an approved drug.
- Class
- Chimeric anticancer peptide (p53-derived / cell-penetrating domain fusion)
- Status
- Preclinical research compound; not approved for any therapeutic use
- Best-supported effect
- Selective killing of cancer cell lines in vitro by binding membrane-associated HDM-2 and inducing pore formation and necrosis, with matched normal cells consistently spared (in vitro assays only)
- Main caveat
- No human clinical trials; all efficacy evidence is in vitro cell culture; in vitro selectivity does not establish in vivo safety or efficacy
A researcher, an agent, or an algorithm wrote down the sequence and picked a target to hit.
An AI model like OpenFold3 or AlphaFold built a 3D structure and scored how well it fits the binding site.
A second contributor repeated the computation on their own hardware and the scores matched.
A chemistry service or a researcher ordered the sequence, it was manufactured, and mass spectrometry confirmed the right molecule was produced.
A binding or activity measurement confirmed that it actually does what the computer predicted — or didn't.
Snapshot
Class: Chimeric anticancer peptide (p53-derived / cell-penetrating domain fusion)
Evidence tier: In vitro / assay evidence
Status: Preclinical research compound; not approved for any therapeutic use
Best-supported effect: Selective killing of cancer cell lines in vitro by binding membrane-associated HDM-2 and inducing pore formation and necrosis, with matched normal cells consistently spared (in vitro assays)
Main caveat: No human clinical trials; all efficacy evidence is in vitro cell culture; in vitro selectivity does not establish in vivo safety or efficacy
What this is
PNC-27 is a 32-amino-acid chimeric peptide designed to exploit a structural difference between cancer cells and normal cells. It fuses two functional domains: an HDM-2 (human double minute 2, also called MDM2)-binding segment derived from the tumor suppressor p53 (residues 12–26), and the antennapedia-derived cell-penetrating peptide penetratin. The design was originally intended as an intracellular p53–HDM-2 disruptor, but the discovered mechanism is different: cancer cells express HDM-2 on their plasma membranes, while normal cells confine HDM-2 to the nucleus. PNC-27 binds this surface-expressed HDM-2 and forms transmembrane pores, inducing necrotic lysis of cancer cells while leaving matched normal cells unharmed. A 2024 study added a second mechanism — mitochondrial membrane disruption upon intracellular entry. Despite mechanistically consistent in vitro results across multiple cancer types and publication in PNAS, PNC-27 has not advanced to human clinical trials.
Evidence map
| Evidence layer | Grade | What it supports |
|---|---|---|
| Human | None identified | No human trial data is present |
| Animal | Weak | Source describes limited in vivo data; individual animal study data are not extracted |
| In vitro | Moderate | Selective killing of cancer cell lines (pancreatic, breast, ovarian, cervical, leukemia) vs. matched normal cells; synergy with paclitaxel in ovarian cancer cells; confirmed by antibody-blocking and gain-of-function experiments |
| Computational | None identified | No computational or docking data identified |
| Mechanism | Strong | Primary mechanism well-characterized: membrane HDM-2 binding → pore formation → necrosis (PNAS 2010, structural and gain-of-function data); secondary mitochondrial disruption mechanism described in 2024 follow-up |
Source concentration note: The published evidence base originates predominantly from one research group (Pincus, Michl, and collaborators at SUNY Downstate Medical Center). Independent replication across external groups is a key limitation of the current evidence base.
Claim check
| Claim | Verdict | Evidence layer | Confidence |
|---|---|---|---|
| Selective killing of cancer cell lines while sparing matched normal cells | Supported (in vitro) | In vitro | Medium — consistent across multiple cancer types in one research group; no independent external replication data extracted in this card |
| Activity across multiple cancer types (pancreatic, breast, ovarian, cervical, leukemia) | Supported (in vitro) | In vitro | Medium — breadth of cell lines is a strength; all from in vitro assays in one research program |
| Works independently of p53 status — kills p53-deleted cancer cells | Supported (in vitro) | In vitro | Medium — mechanism is membrane HDM-2 binding, not p53 reactivation; supported by cell-line data and mechanism studies |
| Synergy with paclitaxel | Supported (in vitro) | In vitro | Low — demonstrated in ovarian cancer cell culture only; no animal or human combination data |
| Dual mechanism: plasma-membrane pore formation and mitochondrial disruption | Partially supported (in vitro) | In vitro | Low — primary pore-formation mechanism is well-supported (PNAS 2010); mitochondrial disruption described in a single 2024 follow-up paper |
| Anticancer efficacy in humans or animals | Not established | None | High — no human trial data; animal in vivo work described as limited in source; in vitro selectivity does not establish in vivo efficacy |
Assay conditions
This section reports concentrations and conditions used in published in vitro assays. It does not establish animal or human exposure.
| Context | System | Assay condition | Timepoint | Endpoint | Limitation |
|---|---|---|---|---|---|
| In vitro cytotoxicity | Cervical cancer cell line (HTB-35) vs. matched normal cells | Approximately 12.4 µM (published IC50) | 24–72 hours (typical for cell-killing endpoints) | Cell lysis / necrosis | In vitro only; micromolar IC50 is high relative to typical systemic oncology drugs; translation to in vivo exposure is uncharacterized |
| In vitro cytotoxicity | Pancreatic, breast, ovarian, leukemia cancer cell lines vs. matched normal cell lines | Micromolar concentration range; exact values not individually extracted for all lines | 24–72 hours | Selective cancer cell killing; normal cell sparing | Same limitations; individual assay conditions not uniformly extracted in this card |
| In vitro combination | Ovarian cancer cell lines | PNC-27 + paclitaxel; concentrations not individually extracted | Not specified | Combined cytotoxicity (synergy) | Single cell-culture system; no in vivo or human data for this combination |
Assay limitations
- All cytotoxicity evidence is from cell culture systems. In vitro selectivity for cancer cells over normal cells has not been confirmed in in vivo animal models with individually documented study data.
- The published IC50 (~12.4 µM in cervical cancer cells) is high relative to the concentration achievable systemically with a 32-amino-acid peptide. Pharmacokinetic, biodistribution, and in vivo exposure data are absent.
- Animal in vivo work is described in available literature as limited; detailed in vivo efficacy or safety data are not individually extracted.
- Immunogenicity of the peptide (containing the antennapedia penetratin sequence) with repeated exposure has not been formally assessed.
- No human safety data are identified.
- Independent replication by external research groups is not documented in the available literature.
Regulatory status
No approved therapeutic status identified. PNC-27 is not approved for any therapeutic indication by FDA, EMA, MHRA, Health Canada, or any other major regulatory authority. No active clinical development program under an approved IND is described in the available literature. PNC-27 is available through research-chemical and research-reagent suppliers for laboratory use only; these sources are not authorized for human use.
| Region / body | Status | Notes |
|---|---|---|
| US | Not approved | Not FDA-approved; no active published IND; not a dietary supplement; not a recognized compounded medication |
| EU / International | Not approved | Per available sources, no EMA, MHRA, TGA, or Health Canada approval; no active international clinical development program described |
| WADA | Not listed on Prohibited List (per available sources) | Source notes the WADA S0 "non-approved substances" clause may apply as it does to any unapproved peptide; status not independently refreshed in this card |
Mechanism
PNC-27 is a chimeric peptide comprising two fused domains: the HDM-2-binding region of human p53 (residues 12–26), which adopts a conformation matching p53 when bound to HDM-2, and the antennapedia-derived cell-penetrating peptide penetratin.
The mechanistic basis for selectivity rests on a differential subcellular localization of HDM-2: cancer cells express HDM-2 on their plasma membranes (residues 1–109 accessible extracellularly), while normal cells restrict HDM-2 to the nucleus. PNC-27 binds to this surface-expressed HDM-2 on cancer cell membranes with high affinity. Following binding, the penetratin domain enables PNC-27 to insert into the lipid bilayer and form transmembrane pores, inducing necrotic lysis.
Target specificity is supported by blocking experiments: anti-HDM-2 antibodies directed at residues 1–109 (the p53-binding site) abolish PNC-27 cytotoxicity. A gain-of-function experiment demonstrated that engineering normal cells to express membrane HDM-2 rendered them susceptible to PNC-27 killing, directly confirming the surface HDM-2 requirement.
A 2024 follow-up study described a secondary mechanism: upon intracellular entry, PNC-27 also disrupts mitochondrial membranes, while leaving lysosomes intact. This dual mechanism — plasma membrane pore formation and mitochondrial disruption — may contribute to the overall cytotoxic effect, though the relative contribution of each mechanism in different cancer cell types has not been fully characterized.
Because PNC-27 acts through direct membrane pore formation rather than through p53-dependent apoptosis pathways, it retains activity in cancer cells with deleted or non-functional p53, distinguishing it mechanistically from nutlin-class p53 reactivators.
Chemistry
| Field | Value |
|---|---|
| Peptide type | Chimeric: p53 transactivation domain fragment (residues 12–26) fused to antennapedia penetratin cell-penetrating sequence |
| Length | 32 amino acids (per available sources) |
| Topology | Linear |
| Key structural feature | p53-like binding conformation when engaging HDM-2, enabling high-affinity interaction |
| Sequence | Full sequence not individually extracted's available literature |
| Sequence confidence | Not established in this card |
| Nanoparticle conjugate | PNC-27/PEI-superparamagnetic iron oxide nanoparticle (PNC-27/PEI-SPION) conjugate described for targeted delivery and diagnostic imaging (preclinical) |
Open questions
- Human translation: No human clinical trial of any phase has been published. Whether the in vitro selectivity for cancer cells over normal cells translates to in vivo animal efficacy or human benefit is entirely unknown.
- In vivo animal efficacy: The in vitro evidence base is consistent but cannot substitute for in vivo tumor model data (xenograft, syngeneic, orthotopic). Systematic in vivo efficacy data with PNC-27 monotherapy or combination regimens are described as limited in available literature.
- Pharmacokinetics: Absorption, distribution, metabolism, and excretion of the parent peptide and its nanoparticle conjugates have not been characterized in any species.
- In vivo safety: The consistent in vitro sparing of normal cells is mechanistically credible but has not been validated in a living organism. Effects on rapidly dividing normal tissues (gut epithelium, bone marrow) in vivo are unknown.
- Immunogenicity: As a 32-amino-acid peptide containing the antennapedia sequence, PNC-27 is plausibly immunogenic with repeated exposure. No formal immunogenicity assessment has been published.
- Resistance mechanisms: Whether cancer cells can downregulate surface HDM-2 expression or develop other resistance mechanisms under sustained PNC-27 exposure has not been studied.
- Systemic exposure feasibility: The in vitro IC50 (~12.4 µM in cervical cancer cells) is high for a systemically administered agent. Achieving and maintaining effective concentrations at tumor sites without systemic toxicity has not been addressed in an in vivo pharmacokinetic model.
- Independent replication: The published evidence base is concentrated in a single research group. Independent replication in external laboratories would strengthen confidence in the mechanism and selectivity findings.
Research directions for this peptide, selected from the current sources — hypotheses you can explore and model. None of it is proven yet; tap any one to see the full thinking.
Is the sequence currently recorded for PNC-27 only the part that finds the tumor target, leaving out the part that actually kills the cancer cell?
Correcting this annotation would prevent scientists from designing experiments or analogs based on an incomplete molecule, saving years of potential misdirected research effort and research funding.
Would PNC-27 only kill cancer cells that make unusually large amounts of its target protein, making that protein level a simple predictive test?
If true, a cheap standard tumor gene test could identify the subset of cancer patients most likely to respond to PNC-27-based therapy, increasing success rates in clinical trials and getting the right drug to the right patients.
Do cancer cells get stuck with this peptide and die because they expose a negatively charged fat on their outer surface that normal cells keep hidden inside?
If true, it would explain why this peptide spares normal cells and would allow researchers to make stronger versions that exploit this cancer-specific surface signature, potentially applicable across many tumor types.
Do the damaged aging cells that drive inflammation in old age display the same surface protein that this cancer peptide uses to find and kill tumor cells?
If true, PNC-27 could be repurposed as an anti-aging therapy that clears the accumulating dysfunctional cells linked to conditions like arthritis, fibrosis, and frailty, offering a new approach to extending healthy lifespan.
Could replacing the penetratin piece of PNC-27 with a shorter, more stable cancer-killing segment keep the anti-cancer activity while making the molecule last longer and cause fewer immune side effects?
If true, it would revive a promising cancer-killing peptide that has stalled in preclinical development due to stability problems, potentially bringing a selective cancer-killing therapy closer to clinical testing.
▸full evidence table2 metrics
| metric | value | tool |
|---|---|---|
| ipTM | 0.44211331009864807 | openfold3-mlx |
| ranking score | 0.589282751083374 | openfold3-mlx |
▸structural qualityopenfold3
| metric | value | note |
|---|---|---|
| gpde | 0.645 | global PDE — lower = better |
| disorder | 0.157 | fraction disordered |
| chain pair ipTM (A, B) | 0.442 | interface quality |
▸3-letter notation
▸recipeopenfold3-mlx 0.3.1
| parameter | value |
|---|---|
| model | openfold3-mlx 0.3.1 |
| weights | — |
| hardware | — |
| mlx version | — |
| python | — |
| random seed | — |
| msa strategy | — |
| diffusion samples | 1 |
| runtime | 88s |
| predicted by | mlx@peptide |
| predicted at | 2026-05-03 |
▸citationbibtex
@peptide{pep10959,
sequence = {PLFEDMPDDELRIEADDPD},
target = {anticancer},
author = {peptidemodel},
year = {2026},
status = {computed}
}